These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19454499)

  • 1. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.
    Chiecchio L; Dagrada GP; Protheroe RK; Stockley DM; Smith AG; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Jul; 94(7):1024-8. PubMed ID: 19454499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia.
    Taniwaki M; Nishida K; Takashima T; Nakagawa H; Fujii H; Tamaki T; Shimazaki C; Horiike S; Misawa S; Abe T
    Blood; 1994 Oct; 84(7):2283-90. PubMed ID: 7919347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer.
    Dib A; Glebov OK; Shou Y; Singer RH; Kuehl WM
    DNA Repair (Amst); 2009 Mar; 8(3):330-5. PubMed ID: 19064000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.
    Yamamoto K; Yakushijin K; Ito M; Goto H; Higashime A; Kajimoto K; Hayashi Y; Matsuoka H; Minami H
    Cancer Genet; 2020 Apr; 242():35-40. PubMed ID: 32035866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-myc overexpression is not mandatory in aggressive-phase multiple myeloma with Burkitt's type translocation.
    Kuroda J; Kimura S; Akaogi T; Hayashi H; Nishida K; Taniwaki M; Kashima K; Abe T; Kobayashi Y; Kondo M
    Ann Hematol; 2000 Sep; 79(9):514-8. PubMed ID: 11043423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
    Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
    Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
    Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
    Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations.
    Mugneret F; Sidaner I; Favre B; Manone L; Maynadié M; Caillot D; Solary E
    Leukemia; 1995 Feb; 9(2):277-81. PubMed ID: 7869764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
    Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
    Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
    Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
    Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
    Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
    Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetics of multiple myeloma.
    Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
    Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
    Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
    Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
    Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
    Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.